ClinicalTrials.gg
CompletedNCT04702776PRO-087Updated Feb 20, 2026Results posted

Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.

A Phase 4 interventional study of Sodium hyaluronate 0.1%/chondroitin sulfate 0.18% and Sodium hyaluronate 0.15% in Dry Eye, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.

Enrollment
3rd of 18
182 · median 88
Started
2021
with 2 others
Phase 4
5 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
2 of 18
Laboratorios Sophia S.A de C.V.

Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 4, and was the 13th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in patients with mild to moderate dry eye disease.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being capable of voluntarily grant a signed .
  • Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
  • Age ≥ 18 years old
  • Women in child-bearing age must assure the continuation (start ≥ 30 days prior to informed consent signing) of a hormonal method or intrauterine device (IUD) during the study.
  • Presenting a mild to moderate dry eye disease diagnosis, defined as:

    • OSDI score ≥ 13, plus one of the following:

      • More than 5 dots of corneal staining
      • More than 9 dots of conjunctival staining
      • Tear break-up time \< 10 seconds

Exclusion criteria

Exclusion Criteria:

  • - Pregnancy, breastfeeding or planning to become pregnant during the time of the study
  • Having participated in clinical trials within 30 days prior to the eligibility visit.
  • Having participated previously in this study.
  • BCVA equal or worse than 20/200, in either eye.
  • Diagnosis of any of the following:

    • Allergic, viral or bacterial conjunctivitis
    • Anterior blepharitis
    • Parasite infestation of any ocular or annex structures (Demodex, for example)
    • Unresolved history of ocular trauma
    • Scarring diseases of the ocular surface
    • Corneal or conjunctival ulcers
    • Filamentary keratitis
    • Neurotrophic keratitis
    • Bullous keratopathy
    • Neoplastic diseases of the ocular surface or ocular annexes
    • Diseases presenting fibrovascular proliferations on the corneal or conjunctival surface.
    • Any retinal or posterior segment diseases that require treatment or threat the visual outcome.
    • Glaucoma
    • Any palpebral alteration that causes eyelid malposition, limiting the adequate closure or aperture of this structures, or that cause tearing.
  • Requiring management for dry eye that includes implementation of treatments described in the step 2 management recommendations of the Tear Film \& Ocular Surface Society's Dry Eye Work Shop II (TFO DEWS II).
  • Previous history of drug addiction within the last 2 years prior to signing this study's form.
  • Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
  • Being a contact lens user, rigid or soft. Inclusion is possible if the use of contact lenses is suspended both during the study period and at least 15 days prior inclusion takes place.
  • Previous history of any medical affliction, acute or chronic, that according to the investigator may increase either the risk to the patient for participating in this study or the risk of interference of the accurate interpretation of results.
  • Known to any of the components of the products used in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Arm 1; Humylub Ofteno® PF

    Humylub Ofteno® PF (sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) ophthalmic solution applied QID for 30 days.

    Drug: Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%

  • Active comparator
    Arm 2; Hyabak®

    Hyabak® PF (sodium hyaluronate 0.15%) ophthalmic solution applied QID for 30 days.

    Drug: Sodium hyaluronate 0.15%

  • Active comparator
    Arm 3; Lagricel Ofteno® PF

    Lagricel Ofteno® PF (sodium hyaluronate 0.4%) ophthalmic solution applied QID for 30 days.

    Drug: Sodium hyaluronate 0.4%

Interventions

  • DrugSodium hyaluronate 0.1%/chondroitin sulfate 0.18%

    Drug page: Hyaluronic Acid

    Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.

    Also known as: Humylub Ofteno® PF, PRO-087

  • Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.

    Also known as: Hyabak® PF

  • Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.

    Also known as: Lagricel Ofteno® PF, PRO-037

06

What researchers measure

Primary outcomes

  1. Change in Ocular Surface Disease Index (OSDI)

    OSDI is a 12-item questionnaire used to evaluate symptoms associated with dry eye disease, as well as classify their severity. According the obtained score, categories are as follows: normal (0-12 points), mild (13-22 points), moderate (23-32 points), or severe (33-100 points). A higher score is a worse outcome. • This outcome measure considered the Per Protocol (PP) population.

    Time frame: Days: 0 (± 2) (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

Secondary outcomes

  1. Noninvasive Keratograph Break-up Time (NIKBUT)

    This evaluation will be performed through an Oculus Keratograph 5M, and the parameter "first break-up time" will be recorded as NIKBUT. A lower value is a worse outcome. This outcome measure considered the Per Protocol (PP) population.

    Time frame: Days: 0 - 2 (baseline visit),17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

  2. Change of Conjunctival and Corneal Staining With Lissamine Green

    The change in proportion of participant's abscence of conjunctival and corneal staining with lissamine green will be analyzed. The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.

    Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

  3. Change of Conjunctival and Corneal Staining With Fluorescein

    The change in proportion of participant's abscence of conjunctival and corneal staining with fluorescein will be analyzed. The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.

    Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

  4. Change in Conjunctival Hyperemia

    The change in proportion of participant's score will be analyzed. Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (3), and Severe (4). This outcome measure considered the Per Protocol (PP) population.

    Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

  5. Incidence of Related Non Expected Adverse Events

    Number of related non expected adverse events observed per group. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

    Time frame: Days: 0 (eligibility visit), 0 - 2 (baseline visit),17 - 19 (± 1) (first follow-up visit), 31 - 33 (± 1) (final visit), and 38 - 40 (± 1) (safety call).

  6. Change in Best Corrected Visual Acuity (BCVA)

    With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20. This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

    Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

  7. Change in Incidence of Chemosis

    Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent per subject. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

    Time frame: Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).

07

Results

Posted Jan 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Started616160
Completed565652
Not completed558
Withdrew: Adverse event121
Withdrew: Lost to follow-up214
Withdrew: Protocol violation223

Outcome measures

PrimaryChange in Ocular Surface Disease Index (OSDI)

OSDI is a 12-item questionnaire used to evaluate symptoms associated with dry eye disease, as well as classify their severity. According the obtained score, categories are as follows: normal (0-12 points), mild (13-22 points), moderate (23-32 points), or severe (33-100 points). A higher score is a worse outcome. • This outcome measure considered the Per Protocol (PP) population.

Time frame:
Days: 0 (± 2) (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Mean · score on a scale
Change in Ocular Surface Disease Index (OSDI)
score on a scaleArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Elegibility visit26.4 ± 5.126.3 ± 5.826.6 ± 4.9
First follow-up visit16.4 ± 8.314.0 ± 10.415.2 ± 8.3
Final visit11.2 ± 9.48.8 ± 7.510.7 ± 9.0
SecondaryNoninvasive Keratograph Break-up Time (NIKBUT)

This evaluation will be performed through an Oculus Keratograph 5M, and the parameter "first break-up time" will be recorded as NIKBUT. A lower value is a worse outcome. This outcome measure considered the Per Protocol (PP) population.

Time frame:
Days: 0 - 2 (baseline visit),17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Mean · seconds
Noninvasive Keratograph Break-up Time (NIKBUT)
secondsArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Baseline visit6.8 ± 3.95.2 ± 3.07.1 ± 4.3
First follow-up visit7.3 ± 4.86.9 ± 4.87.7 ± 4.9
Final visit8.7 ± 5.37.8 ± 4.97.1 ± 3.9
SecondaryChange of Conjunctival and Corneal Staining With Lissamine Green

The change in proportion of participant's abscence of conjunctival and corneal staining with lissamine green will be analyzed. The evaluation will take place after applying the lissamine green stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.

Time frame:
Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Count of participants · Participants
Change of Conjunctival and Corneal Staining With Lissamine Green
ParticipantsArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Eligibility visit — 0202316
Eligibility visit — I212224
Eligibility visit — II340
Eligibility visit — III200
Eligibility visit — IV000
First follow-up visit — 0252825
First follow-up visit — I161912
First follow-up visit — II413
First follow-up visit — III010
First follow-up visit — IV100
Final visit — 0333223
Final visit — I121517
Final visit — II120
Final visit — III000
Final visit — IV000
SecondaryChange of Conjunctival and Corneal Staining With Fluorescein

The change in proportion of participant's abscence of conjunctival and corneal staining with fluorescein will be analyzed. The evaluation will take place after applying the fluorescein stain on the ocular surface and evaluating the resulting staining pattern. This will be measured through the Oxford scale which includes 6 grades: Absent (0), Minimal (I), Mild (II), Moderate (III), Marked (IV), Severe (V). This outcome measure considered the Per Protocol (PP) population.

Time frame:
Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Count of participants · Participants
Change of Conjunctival and Corneal Staining With Fluorescein
ParticipantsArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Elegibility visit — 0192016
Elegibility visit — I192720
Elegibility visit — II724
Elegibility visit — III100
First follow-up visit — 0312325
First follow-up visit — I122214
First follow-up visit — II341
First follow-up visit — III000
Final visit — 0363424
Final visit — I101514
Final visit — II002
Final visit — III000
SecondaryChange in Conjunctival Hyperemia

The change in proportion of participant's score will be analyzed. Rate of conjunctival hyperemia will be evaluated through the Efron scale which includes 5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (3), and Severe (4). This outcome measure considered the Per Protocol (PP) population.

Time frame:
Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Count of participants · Participants
Change in Conjunctival Hyperemia
ParticipantsArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Elegibility visit — Normal211514
Elegibility visit — Very Mild141712
Elegibility visit — Mild91511
Elegibility visit — Moderate223
Elegibility visit — Severe000
First follow-up visit — Normal232222
First follow-up visit — Very Mild172214
First follow-up visit — Mild654
First follow-up visit — Moderate000
First follow-up visit — Severe000
Final visit — Normal323327
Final visit — Very Mild111413
Final visit — Mild320
Final visit — Moderate000
Final visit — Severe000
SecondaryIncidence of Related Non Expected Adverse Events

Number of related non expected adverse events observed per group. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Time frame:
Days: 0 (eligibility visit), 0 - 2 (baseline visit),17 - 19 (± 1) (first follow-up visit), 31 - 33 (± 1) (final visit), and 38 - 40 (± 1) (safety call).
Reported as:
Number · adverse events
Incidence of Related Non Expected Adverse Events
adverse eventsArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Incidence of Related Non Expected Adverse Events5510
SecondaryChange in Best Corrected Visual Acuity (BCVA)

With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20. This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.

Time frame:
Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Mean · decimal
Change in Best Corrected Visual Acuity (BCVA)
decimalArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Elegibility visit0.97 ± 0.180.95 ± 0.210.94 ± 0.20
First follow-up visit0.99 ± 0.170.98 ± 0.260.96 ± 0.22
Final visit0.99 ± 0.20.96 ± 0.180.96 ± 0.22
SecondaryChange in Incidence of Chemosis

Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent per subject. This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Time frame:
Days: 0 (eligibility visit), 17 - 19 (± 1) (first follow-up visit), and 31 - 33 (± 1) (final visit).
Reported as:
Count of participants · Participants
Change in Incidence of Chemosis
ParticipantsArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Elegibility visit000
First follow-up visit000
Final visit000

Adverse events

Collected over Adverse event data was recollected starting from the elegibility visit (day 0) until the security call (day 38 - 40) done at the end of the study. In this study, AE were collected during of 1 year, 5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1; Humylub Ofteno® PF0/61 (0%)1/61 (1.6%)40/61 (65.6%)
Arm 2; Hyabak®0/61 (0%)0/61 (0%)39/61 (63.9%)
Arm 3; Lagricel Ofteno® PF0/60 (0%)0/60 (0%)43/60 (71.7%)
Most frequent serious events
Most frequent serious events
EventArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Convulsive CrisisNervous system disorders1/610/610/60
Most frequent other events
Most frequent other events
EventArm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PF
Ocular burningEye disorders27/6129/6130/60
PruritusEye disorders11/615/6115/60
Foreign body sensation in the eyeEye disorders5/612/619/60
HeadacheNervous system disorders0/610/613/60
EyestrainEye disorders2/610/612/60
TearingEye disorders2/611/612/60
Ocular hyperemiaEye disorders1/612/610/60

Baseline characteristics

The manifested adverse events during the conduction of this trial were obtained during trial visits and reported in the electronic CRF, where the clinical team of the center included the information from source documents. These were previously checked by the monitor team, pharmacovigilance specialist, and the medical specialist part of the sponsor's crew to verify concordance with what was stipulated in the protocol.

Age, Categorical
Age, Categorical(Participants)Arm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PFTotal
<=18 years0000
Between 18 and 65 years616160182
>=65 years0000
Age, Continuous
Age, Continuous(years)Arm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PFTotal
Mean29.5 ± 1131.7 ± 11.731.4 ± 10.230.9 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PFTotal
Female333336102
Male28282480
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PFTotal
Hispanic or Latino616160182
Not Hispanic or Latino0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Arm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PFTotal
Mexico616160182
Conjunctival hyperemia
Conjunctival hyperemia(Participants)Arm 1; Humylub Ofteno® PFArm 2; Hyabak®Arm 3; Lagricel Ofteno® PFTotal
Count of participants24191659
08

Study locations

1 site
  • Unidad Clínica de Bioequivalencia, S. de R.L. de C.V.
    Guadalajara, Jalisco 44190, Mexico
09

References and documents

Publications

  • Munoz-Villegas P, Garcia-Sanchez G, Jauregui-Franco RO, Quirarte-Justo S, Sanchez-Rios A, Olvera-Montano O. Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease. Clin Ophthalmol. 2024 Aug 30;18:2439-2451. doi: 10.2147/OPTH.S480223. eCollection 2024. PubMed 39233999 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2023, 17 months.

Results were first posted in Jan 2026, 2 years 7 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 17 months is above that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Dec 9, 2021
Primary completionActual
May 15, 2023
CompletionActual
May 15, 2023
Results first posted
Jan 13, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04702776
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Dec 9, 2021
Primary completion
May 15, 2023
Completion
May 15, 2023
Results posted
Jan 13, 2026
Last update
Feb 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion